Size : | Price | Quantity | |
---|---|---|---|
5 mg | $38.00 | ||
25 mg | $120.00 |
Docetaxel (114977-28-5) is an antimitotic chemotherapeutic which inhibits via reversible high-affinity binding to microtubules1. Induces apoptosis in a variety of cancer cell lines2 however, tumor cells can quickly develop resistance to docetaxel via several mechanisms3,4. Docetaxel can act in synergy with a variety of other anticancer agents including kinase inhibitors.5,6
References/Citations:
1) Fabbri et al. (2008), Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells; J. Cell Physiol, 217 494
2) Dosso and Berthold (2008), Docetaxel in the management of prostate cancer: current standard of care and future directions; Expert Opin. Pharmacother, 9 1969
3) Homma et al. (2008), RPN2 gene confers docetaxel resistance in breast cancer; Nat. Med., 14 939
4) Kars et al. (2008), Reversal of Multidrug Resistance by Synthetic and Natural Compounds in Drug-Resistant MCF-7 Cell Lines; Chemotherapy, 54 194
5) Wallin et al. (2012), GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In vitro and In vivo; Clin Cancer Res., 18 3901
6) Heinemann et al. (2011), Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer; BMC Cancer, 11 221
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Docetaxel (114977-28-5) is an antimitotic chemotherapeutic which inhibits via reversible high-affinity binding to microtubules1. Induces apoptosis in a variety of cancer cell lines2 however, tumor cells can quickly develop resistance to docetaxel via several mechanisms3,4. Docetaxel can act in synergy with a variety of other anticancer agents including kinase inhibitors.5,6
References/Citations:
1) Fabbri et al. (2008), Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells; J. Cell Physiol, 217 494
2) Dosso and Berthold (2008), Docetaxel in the management of prostate cancer: current standard of care and future directions; Expert Opin. Pharmacother, 9 1969
3) Homma et al. (2008), RPN2 gene confers docetaxel resistance in breast cancer; Nat. Med., 14 939
4) Kars et al. (2008), Reversal of Multidrug Resistance by Synthetic and Natural Compounds in Drug-Resistant MCF-7 Cell Lines; Chemotherapy, 54 194
5) Wallin et al. (2012), GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In vitro and In vivo; Clin Cancer Res., 18 3901
6) Heinemann et al. (2011), Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer; BMC Cancer, 11 221
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.